Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.63 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.56 |
| ▸ | STS | P08842 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SHBG | P04278 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707483 | 0.95 | ESR1 (0.69) | ESR1ESR2HSD17B1STSCYP3A4 | |
| SCHEMBL7102035 | 0.93 | ESR1 (0.67) | ESR1ESR2HSD17B1STSCYP3A4 | |
| SCHEMBL5707604 | 0.87 | ESR1 (0.74) | ESR1ESR2HSD17B1STSCYP3A4 | |
| SCHEMBL7650371 | 0.86 | ESR1 (0.58) | ESR1ESR2STSCYP3A4MAPT | |
| SCHEMBL7213165 | 0.86 | ESR1 (0.65) | ESR1ESR2HSD17B1STSCYP3A4 | |
| SCHEMBL5707521 | 0.85 | ESR1 (0.59) | ESR1ESR2HSD17B1STSMAPT | |
| SCHEMBL5159033 | 0.85 | ESR1 (0.71) | ESR1ESR2HSD17B1STSCYP3A4 | |
| SCHEMBL7218327 | 0.85 | ESR1 (0.71) | ESR1ESR2HSD17B1STSCYP3A4 | |
| SCHEMBL7949541 | 0.85 | ESR1 (0.77) | ESR1ESR2HSD17B1STSCYP3A4 | |
| SCHEMBL7218332 | 0.84 | ESR1 (0.70) | ESR1ESR2HSD17B1STSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147124-B1 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | UNIV HOLY GHOST DUQUESNE (US) | 2006-08-30 | — | — | EP | disclosed |
| US-6638923-B2 | Has inhibitory activity against steroid sulfatase and are useful in treating or preventing hormone dependent diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| US-6436918-B1 | SULFAMATE- AND AMINOCARBONYL- SUBSTITUTED STEROID RING SYSTEM HAVING 4 ATTACHED RINGS; THERAPEUTIC AND PROPHYLACTIC TREATMENTS FOR ESTROGEN DEPENDENT ILLNESSES. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-08-20 | — | — | US | disclosed |
| US-20020068726-A1 | Steroid sulfatase inhibitors and methods for making and using the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2002-06-06 | — | — | US | disclosed |
| US-6399595-B1 | ANTITUMOR AGENTS; MAMMARY GLANDS | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-06-04 | — | — | US | disclosed |
| US-20020058651-A1 | Estra-1,3,5(10), 16-tetraene derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376687-B1 | THERAPY FOR ESTROGEN SENSITIVE DISEASES | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-04-23 | — | — | US | disclosed |
| US-6288050-B1 | ADMINISTERING ESTRANESULFAMIC ACID DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2001-09-11 | — | — | US | disclosed |
| US-6262043-B1 | SHOW INHIBITORY ACTIVITY AGAINST STEROID SULFATASE AND ARE USEFUL IN TREATING OR PREVENTING HORMONE DEPENDENT DISEASES. | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058651-A1 | Estra-1,3,5(10), 16-tetraene derivatives | HSD17B11, NR5A1, CYP19A1 | ESR1 7/4885ESR2 5/4885HSD17B1 9/4885 |
| US-20020068726-A1 | Steroid sulfatase inhibitors and methods for making and using the same | STS, HSD17B11, CYP21A2 | ESR1 58/4885ESR2 45/4885HSD17B1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.